ME Therapeutics Obtains U.S. Patent for Key Candidate and Progresses Additional Therapeutic Initiatives

Patent Acquisition: ME Therapeutics has secured a U.S. patent for its G-CSF antibody candidate, which targets immune suppression in the tumor microenvironment, marking its second international patent for this candidate.

Advancements in Drug Development: The company is progressing its drug development pipeline, including cell line development for clinical trials, preclinical testing of therapeutic mRNA candidates, and discovery of in vivo CAR programs, while expanding its research team.